Open AccessTheophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?
Author(s) -
Paul Billoir,
Thomas Clavier,
Arnaud Guilbert,
Virginie Barbay,
Marie Hélène Chrétien,
Marielle Fresel,
Caroline Abriou,
Christophe Girault,
Véronique Le Cam Duchez
Publication year - 2020
Publication title -
annales de biologie clinique
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.167
H-Index - 27
eISSN - 1950-6112
pISSN - 0003-3898
DOI - 10.1684/abc.2020.1525
Subject(s) - chemistry , anticoagulant , heparin , theophylline , partial thromboplastin time , centrifugation , dipyridamole , pharmacology , platelet , chromatography , medicine , biochemistry
Unfractionated heparin (UFH) is the main anticoagulante used in intensive care unit. The anticoagulant effect is monitored by activated partial thrombin time (aPTT) and anti-Xa activity (anti-Xa) measurement. However, delayed centrifugation induces platelet factor 4 (PF4) release and anti-Xa decrease. Several studies have concluded that aPTT and anti-Xa measurement should be performed within 2 hours in citrated anticoagulant but may be delayed longer in citrate theophylline adenosine and dypiridamol (CTAD) anticoagulant. The objective of this study was to compare the stability of both aPTT and anti-Xa in citrate and CTAD samples, and to determine the effect of delayed centrifugation on both aPTT, anti-Xa results, and PF4 release in citrate samples only.